Ligand Pharmaceuticals Reports $32.4 Million in Revenue for Q1 2026

Ligand Pharmaceuticals Incorporated released its financial results for the first quarter of 2026, revealing key figures regarding revenue, adjusted earnings per share, and cash positions. The report also highlighted the company’s strategic investments and pipeline advancements during the quarter.

Specifically, Ligand reported total revenues of $32.4 million and an adjusted earnings per share of $0.84 for the first quarter. The company concluded the quarter with $169.8 million in cash, cash equivalents, and short-term investments. Ligand also invested $14.0 million in Captisol technology and $6.3 million in OmniAb platform during the quarter, underscoring its commitment to technological advancements.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI